Esperion Therapeutics, Inc. (ESPR)
Esperion Therapeutics, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
Esperion Therapeutics, Inc. (ESPR) is a Biotechnology company based in US with a market capitalization of $661.1M. Revenue grew 21.3% year-over-year and free cash flow was negative at -$13.1M. This page tracks ESPR's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
US · 304 employees · IPO Jun 26, 2013
Valuation
Valuation & price
$3.12as of May 17, 2026· -23.5% vs 52w high
—
P/E ratio
Latest-FY diluted EPS
—
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$661.1M
Market cap
21.3%
Revenue growth (YoY)
68.0%
Gross margin
-$13.1M
Free cash flow (USD)
$380.1M
Net debt
11.1%
Share dilution
0/4
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2016 → 2025
Free cash flow by year
2016 → 2025
Gross margin by year
2021 → 2025
Value screen
Graham defensive-investor tests
0
Insider buys · 90 days
3
Insider sells · 90 days
Earnings
Last report: 10-Q filed May 8, 2026
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
- 8-K eventJul 13, 2026Filing
Contingent Value Rights Agreement
- 8-K eventJul 8, 2026Filing
Merger Agreement Approved
- Insider sellJun 18, 2026Filing
Insider Sell $34KHalladay Benjamin · Chief Financial Officer · $34K
- Insider sellJun 18, 2026Filing
Insider Sell $169KKoenig Sheldon L. · Director, President and CEO · $169.1K
- Insider sellJun 18, 2026Filing
Insider Sell $37KLooker Benjamin · Chief Legal Officer · $37.3K
- 8-K eventJun 18, 2026Filing
Acquisition Completed
- 8-K eventJun 16, 2026Filing
Merger Agreement Update
- 8-K eventJun 9, 2026Filing
Merger Clearance
- 8-K eventJun 1, 2026Filing
Stock Option Plan Established
- Quarterly reportMay 8, 2026Filing
10-Q Filed
Questions
Frequently asked questions
What is Esperion Therapeutics, Inc.'s market cap?
Esperion Therapeutics, Inc. (ESPR) has a market capitalization of $661.1M.
What is ESPR's P/E ratio?
A meaningful P/E ratio is not available for ESPR — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.
Are insiders buying ESPR stock?
SEC Form 4 filings show no open-market insider buys at Esperion Therapeutics, Inc. in the last 90 days (3 sells).
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.